Abstract 1144P
Background
Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer. Early stage cSCC is often cured with simple resection +/- radiotherapy, though some can recur, most commonly in immunosuppressed (IS) individuals. In advanced cSCC, approximately 50% of patients develop primary resistance to immune checkpoint inhibitors (ICI). There is a need to identify biomarkers by characterising the tumour microenvironment (TME) within different clinical groups.
Methods
Our retrospective study profiled whole tissue sections from n=50 patients from the Princess Alexandra Hospital. Study groups (G) included immunocompetent patients with (G1) de novo, localised cSCC (n=10), (G2) regional nodal metastasis (n=10), (G3) locoregional recurrent disease (n=10), (G4) recurrent/metastatic disease treated with ICI (n=10) and (G5) IS patients (n=10). In this exploratory study, we designed a high-dimensional Nanostring GeoMx Digital Spatial Profiling (DSP) experiment which enabled simultaneous readout of >80-plex proteins in the TME to profile immune cell content, immuno-oncology drug targets, cell lineage and architecture. These features within the TME were measured against the clinical groupings to identify differentially expressed proteins between the groups for future biomarker analysis.
Results
Our preliminary analysis has identified distinct cell phenotype compositions within the TME associated with the clinical groupings. Within the tumour there was a reduction in expression of VISTA and STING immune signaling markers in localized disease (G1/2 vs G4). This was most notable within the stomal compartments. G3/4 had a lower expression of IDO1/STING/VISTA immune signaling markers compared with G5 IS individuals. Moreover, we identified an increased metabolic activity in patients with resistant disease.
Conclusions
Our study highlights the utility of spatial proteomic profiling of the TME in cSCC for the identification of biomarkers associated with biologically distinct clinical groups. This study provides the foundation work for prospective validation of putative biomarkers associated with therapy response and resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Metro South Hospital and Health Services.
Funding
Princess Alexandra Research Foundation.
Disclosure
R. Ladwa, S. Porceddu: Financial Interests, Personal, Advisory Board: MSD, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1181TiP - BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Presenter: Philippe Saiag
Session: Poster session 13
1188P - Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Presenter: Anthony Crymes
Session: Poster session 13
1189P - Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Presenter: Annabella Di Mauro
Session: Poster session 13
1191P - TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Presenter: Anna La Salvia
Session: Poster session 13
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13